...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: Zenith Epigenetics Announces Initiation of a Phase 2b Triple Negative Breast Cancer (TNBC) Clinical Trial

"How lomg was this trial supposed to run before they report results? Where can I find the details of this trial?"

Is this not the Trial that involved Pfizer, Newsoara and ZEN-3694 that was discontinued?

(Reference: MD&A Jan 31, 2024 page 2)     "Based on an interim futility analysis, we have decided to discontinue the trial in the USA and EU due to lack of responses in the target population, post-TROP2 directed ADC therapy, most likely due to emergence of very aggressive disease or a resistance mechanism. This study, which was also accruing pre-Trodelvy patients in China has been completed and data analysis is ongoing."

 

Koo

Share
New Message
Please login to post a reply